** Aussie healthcare stocks .AXHJ fall as much as 4.2%,
their biggest decline since Oct 12, if trend holds
** The sub-index hits lowest level since Jan 25
** Biotechnology co CSL slumps 4.4%, and is the top loser on
ASX 200 .AXJO after a failed phase 3 AEGIS-II trial for
evaluating the efficacy and safety of their drug CSL112
** ASX-listed shares of medical device maker Resmed RMD.AX
drop 1.1%
** Cochlear COH.AX and Ramsay Healthcare RHC.AX shed
0.4% and 0.5%, respectively
** Sub-index has risen 5.6% this year as of last close
(Reporting by Poonam Behura in Bengaluru)
((Poonam.Behura@thomsonreuters.com;))